HBIO
HARVARD BIOSCIENCE INC
$6.08
-8.43%
$27.4M
No data for this timeframe.
Vol
Market Cap$27.4M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders16 funds
Inst. Value$2.4M
Insider Activity5B / 0S
Insider Net $$202.4K
SEC Reports8
Recent Activity
Jun 9, 2026
Insider
Benson Seth Benjamin was granted 16,556 shares
Director
Jun 9, 2026
Insider
Gagnon Robert E. was granted 16,556 shares
Director
Jun 9, 2026
Insider
DENELSKY STEPHEN J was granted 16,556 shares
Director
Jun 2, 2026
SEC
Harvard Bioscience held its 2026 Annual Meeting on June 2, 2026, where stockholders approved an amendment to the Employe
8-K — Impact 3/10
May 12, 2026
SEC
Harvard Bioscience filed an 8-K with an investor presentation providing FY26 guidance of 2-4% revenue growth and 6-10% a
8-K — Impact 5/10
May 12, 2026
SEC
Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.6% YoY from $21.8M, and a GAAP net loss of $(3.4)M, improv
PRESS-RELEASE — Impact 4/10
May 12, 2026
earnings
Harvard Bioscience Announces First Quarter 2026 Financial Results
Harvard Bioscience Announces First Quarter 2026 Financial Results
Price Targets
$6.00
-1.3% upside
Hold
Current $6.08
Low $6.00
Median $6.00
High $6.00
1 analysts
$6.00
$6.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 16, 2026 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
| Mar 13, 2026 | Benchmark | MAINTAIN | Speculative Buy → Speculative Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.21 | $-0.35 — $-0.07 | -110% YoY | 2 |
| Next Q | $-0.27 ▼ -370.0% | $-0.54 — $0.00 | 0% YoY | 2 |
| Current FY | $-0.70 ▼ -450.0% | $-1.23 — $-0.17 | -250% YoY | 2 |
| Next FY | $0.44 ▼ -45.0% | $0.30 — $0.58 | 163% YoY | 2 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $795.3K | — |
| TWO SIGMA INVESTMENTS, LP | $555.8K | — |
| RENAISSANCE TECHNOLOGIES LLC | $493.9K | — |
| BlackRock, Inc. | $303.0K | — |
| VANGUARD FIDUCIARY TRUST CO | $135.0K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Benson Seth | A | $0.00 |
| Jun 9, 2026 | Gagnon Robert | A | $0.00 |
| Jun 9, 2026 | DENELSKY STEPHEN | A | $0.00 |
| Jun 9, 2026 | Eade Katherine | A | $0.00 |
| Jun 9, 2026 | Snider William | A | $0.00 |
16 institutional holders with $2.4M total value (499,497 shares) as of 2026-Q1. Top holders: VANGUARD, TWO, RENAISSANCE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 163,313 | $795.3K | 32.7% | — |
| 2 | TWO SIGMA INVESTMENTS, LP | 114,117 | $555.8K | 22.8% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 101,427 | $493.9K | 20.3% | — |
| 4 | BlackRock, Inc. | 62,226 | $303.0K | 12.5% | — |
| 5 | VANGUARD FIDUCIARY TRUST CO | 27,730 | $135.0K | 5.6% | — |
| 6 | STATE STREET CORP | 14,932 | $72.7K | 3.0% | — |
| 7 | CITIGROUP INC | 6,273 | $30.6K | 1.3% | — |
| 8 | FMR LLC | 3,274 | $15.9K | 0.7% | — |
| 9 | GROUP ONE TRADING LLC | 2,182 | $10.6K | 0.4% | — |
| 10 | MORGAN STANLEY | 1,628 | $7.9K | 0.3% | — |
| 11 | Vanguard Global Advisers, LLC | 1,221 | $5.9K | 0.2% | — |
| 12 | ROYAL BANK OF CANADA | 855 | $4.0K | 0.2% | — |
| 13 | NISA INVESTMENT ADVISORS, LLC | 228 | $1.1K | 0.0% | — |
| 14 | FEDERATED HERMES, INC. | 73 | $356.00 | 0.0% | — |
| 15 | PNC FINANCIAL SERVICES GROUP, INC. | 14 | $68.00 | 0.0% | — |
| 16 | CWM, LLC | 4 | $19.00 | 0.0% | — |
7 unique insiders with 12 transactions. Net insider value: $202.4K ($202.4K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Benson Seth Benjamin | Director | AWARD | 16,556 | — | — |
| Jun 9, 2026 | Gagnon Robert E. | Director | AWARD | 16,556 | — | — |
| Jun 9, 2026 | DENELSKY STEPHEN J | Director | AWARD | 16,556 | — | — |
| Jun 9, 2026 | Eade Katherine A. | Director | AWARD | 16,556 | — | — |
| Jun 9, 2026 | Snider William | Director | AWARD | 16,556 | — | — |
| Mar 20, 2026 | Duke John D | Chief Executive Officer | AWARD | 75,000 | — | — |
| Mar 20, 2026 | Frost Mark T | Chief Financial Officer | AWARD | 30,000 | — | — |
| Mar 17, 2026 | DENELSKY STEPHEN J | Director | BUY | 10,000 | $4.87 | $48.7K |
| Mar 17, 2026 | Snider William | Director | BUY | 8,475 | $4.85 | $41.1K |
| Mar 16, 2026 | Frost Mark T | Chief Financial Officer | BUY | 5,000 | $5.00 | $25.0K |
| Mar 16, 2026 | Duke John D | Chief Executive Officer | BUY | 5,000 | $5.01 | $25.1K |
| Mar 16, 2026 | Snider William | Director | BUY | 12,525 | $4.99 | $62.5K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 4 neutral. Avg impact: 4.5/10.
NEUTRAL
8-K
3/10
Harvard Bioscience held its 2026 Annual Meeting on June 2, 2026, where stockholders approved an amen
Jun 2, 2026
MIXED
8-K
5/10
Harvard Bioscience filed an 8-K with an investor presentation providing FY26 guidance of 2-4% revenu
May 12, 2026
NEUTRAL
PRESS-RELEASE
4/10
Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.6% YoY from $21.8M, and a GAAP net los
May 12, 2026
BEARISH
8-K
6/10
Harvard Bioscience reported Q1 2026 revenue of $20.8M, down 4.7% YoY from $21.8M, and a GAAP net los
May 12, 2026
NEUTRAL
CLUSTER
3/10
Analysis based on filing metadata only — document content was unavailable. This is an insider tradin
Apr 1, 2026
NEUTRAL
CLUSTER
3/10
HBIO CEO received a non-cash grant of 75,000 shares, while a director made an open-market purchase o
Mar 23, 2026
BULLISH
CLUSTER
6/10
Two corporate insiders at Harvard Bioscience purchased shares in the open market within the past wee
Mar 18, 2026
MIXED
8-K, PRESS-RELEASE
6/10
Harvard Bioscience reported full-year 2025 revenue of $86.6M, down from $94.1M in 2024, driven by a
Mar 12, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Buy (75% buy). Based on 8 analysts: 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$6.00 mean target
-1.3% upside
Hold (3.00)
$6.00 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $6.08 |
| Target Low | $6.00 |
| Target Mean | $6.00 |
| Target Median | $6.00 |
| Target High | $6.00 |
| # Analysts | 1 |
| Recommendation | Hold (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.21 | $-0.35 | $-0.07 | -110.0% | — | 1↑ 0↓ | $0.0B | 4.9% | 2 |
| Next Q 2026-09-30 |
$-0.27 | $-0.54 | $0.00 | 0.0% | -370.0% | 0↑ 1↓ | $0.0B | 6.1% | 2 |
| Current FY 2026-12-31 |
$-0.70 | $-1.23 | $-0.17 | -250.0% | -450.0% | 0↑ 1↓ | $0.1B | 2.4% | 2 |
| Next FY 2027-12-31 |
$0.44 | $0.30 | $0.58 | 162.9% | -45.0% | 1↑ 0↓ | $0.1B | 6.3% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.210 | |
| 7d ago | $0.020 | -0.230 |
| 30d ago | $0.000 | -0.210 |
| 60d ago | $0.000 | -0.210 |
| 90d ago | $0.300 | -0.510 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 16, 2026 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
| Mar 13, 2026 | Benchmark | MAINTAIN | Speculative Buy | Speculative Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
Harvard Bioscience Announces First Quarter 2026 Financial Results
Harvard Bioscience Announces First Quarter 2026 Financial Results
May 12, 2026
earnings_calendar
HBIO Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
other
Harvard Bioscience to Participate in Upcoming Investor Conferences
Harvard Bioscience to Participate in Upcoming Investor Conferences
Apr 30, 2026
earnings_calendar
HBIO Q1 2026 Earnings Scheduled — 2026-04-30
Apr 28, 2026
earnings
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
Mar 12, 2026
earnings
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Mar 12, 2026
earnings_calendar
HBIO Q4 2025 Earnings After Market Close — 2026-03-12
Mar 6, 2026
other
Harvard Bioscience Announces Reverse Stock Split
Harvard Bioscience Announces Reverse Stock Split
Mar 3, 2026
other
Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum